Exercise and Vascular Parameters in Hemodialysis
2017年4月4日 更新者：Sameena Iqbal
Aerobic Exercise and Vascular Hemodynamic Parameters Among Prevalent Hemodialysis Population
Arterial calcification is very common in the incident hemodialysis population, ranging 71-83%.Given that cardiovascular disease is a major cause of mortality in the hemodialysis population, medial arterial calcification may contribute through increased risk of sudden death and congestive heart failure.
Applanation tonometry is the method of choice to measure pulse wave velocity and pulse wave analysis.
The primary objective will be to assess the effect of a 16 week exercise program on aortic pulse wave velocity as the vascular parameter and gait speed as the physical functioning parameter.
The secondary objectives will assess the effect of the exercise program on ultrafiltration rates, weight, SBP, DBP, BNP, hsTroponin, serum calcium, phosphate, albumin, glucose, LDL, HDL, TG, glycated hemoglobin, hemoglobin, CRP, micro RNAs (21, 126, 133, 146a, 221/222 and 210) and hospitalizations.
調査の概要
詳細な説明
The investigators propose a pilot project to assess the effect of a 16 week aerobic exercise program on arterial stiffness and cardiovascular risk in the hemodialysis population. The primary objective will be to assess the effect of a 16 week exercise program on aortic pulse wave velocity as the vascular parameter and gait speed as the physical functioning parameter. The secondary objectives will assess the effect of the exercise program on ultrafiltration rates, weight, SBP, DBP, BNP, hsTroponin, serum calcium, phosphate, albumin, glucose, LDL, HDL, TG, glycated hemoglobin, hemoglobin, CRP, micro RNAs (21, 126, 133, 146a, 221/222 and 210) and hospitalizations.
Study Design:
Randomized-controlled study of end stage renal disease patients between the age of 18 and 90 years to assess the effect of exercise on arterial stiffness. Our aim is to have 23 patients in both groups. The study period will be 24 weeks-4 weeks for recruitment, 16 weeks for the intervention and 4 weeks for data collection and analysis. The protocol will be submitted to the MUHC Research Ethics Board.
The following outcomes are of interest:
- change in gait speed before and after the exercise program
- change in pulse wave velocity before and after the exercise program
- change in BNP, blood pressure, dialysis ultrafiltration, hemoglobin, micro RNAs before and after the exercise program
研究の種類
介入
入学 (実際)
21
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Quebec
-
Montreal、Quebec、カナダ、H3A 1A1
- Royal Victoria Hospital
-
Montreal、Quebec、カナダ、H3G 1A4
- Montreal General Hospital
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年～95年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Male or female, aged 18-95 years
- Able to comply with the study procedures and medication
- Written informed consent given
- On a stable in-center hemodialysis regimen (at least 3 times per week) for ≥ 12 weeks prior to recruitment
- Cardiac evaluation within the year with adequate cardiac function to be able to undergo the exercise program
Exclusion Criteria:
- Participation in any clinical trial using an investigational product or device during the 30 days preceding recruitment
- Any physical or psychological disability that would impact study participation, such as severe cerebrovascular disease (ie. hemiparesis, cerebellar ataxia, etc.) or dementia
- Serum iPTH > 250 pmol/L within 30 days prior to screening visit
- Dysrhythmia or severe cardiac disease: CHF Class III-IV; unstable cardiovascular diagnosis (for example MI, CABG, PTCA, CVA, and TIA) within 90 days prior to recruitment
- Severe peripheral vascular disease
- Severe hyperkalemia (>6.5 mmol/L) consistently for the last 2 weeks
- Current active cancer (excluding basal cell carcinoma of the skin)
- Poorly controlled hypertension (systolic > 180mmHg or diastolic > 100mmHg) within 4 weeks prior to recruitment
- Anticipated live donor kidney transplant or any other planned major surgery over the study duration
- History of poor adherence to hemodialysis or medical regimen
- Any disease or condition, physical or psychological that, in the opinion of the investigator, would compromise the safety of the subject or the likelihood of achieving reliable results or increase the likelihood of the subject being withdrawn
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の：Aerobic Exercise program
Intervention of aerobic exercise
|
The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs.
The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment.
The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down.
The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks.
Blood pressure and heart continuous monitoring will be carried out during the exercise program.
Exercise log sheets will be filled for each session for the 16 weeks.
|
|
他の：Control
no aerobic exercise program
|
No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Gait speed
時間枠：at 24 weeks and 48 weeks
|
The gait speed will be measured with a timer (in seconds) as the subject will be asked to walk a 10 foot or 3 meter course and back as quickly as possible.
Two readings will be taken and the average will be recorded.
|
at 24 weeks and 48 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline Pulse wave velocity (PWV)
時間枠：at 24 weeks and 48 weeks
|
PWV measurements will be performed between the carotid and femoral artery sites, to primarily measure the stiffness of the aorta.
A 3-lead ECG will be used in conjunction with a tonometer to measure the pressure pulse waveform sequentially in the two peripheral artery sites
|
at 24 weeks and 48 weeks
|
|
Change from Baseline Pulse wave analysis
時間枠：at 24 and 48 weeks
|
Wave Reflections and Arterial Stiffness.
Analysis of the systolic part of the central pressure waveform will be performed to evaluate PWV and the LV afterload.
The main indices that were described above (in hemodynamic measurements) will be obtained by aortic PWA.
|
at 24 and 48 weeks
|
|
Change from baseline Rand survey
時間枠：at 24 weeks and 48 weeks
|
RAND 36-item survey will be used to assess physical functioning and fatigue.
This survey has been validated in the Hemodialysis population.
The survey consists of 36 items and takes approximately 5-10 minutes to complete.
|
at 24 weeks and 48 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
change from baseline micro RNA levels
時間枠：at 24 weeks and 48 weeks
|
micro RNAs (21, 126, 133, 146a, 221/222 and 210): blood sample will be taken before initiation of dialysis week of baseline measurements and end of study.
|
at 24 weeks and 48 weeks
|
|
change from baseline Brain Natuiretic Peptide
時間枠：at 24 weeks and 48 weeks
|
Brain Natuiretic Peptide: measure before initiation of dialysis at baseline and at the end of study period.
|
at 24 weeks and 48 weeks
|
|
change from baseline troponin levels
時間枠：at 24 weeks and 48 weeks
|
to assess myocardial injury during dialysis at baseline and at the end of the study
|
at 24 weeks and 48 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者：Sameena Iqbal、McGill University Health Centre/Research Institute of the McGill University Health Centre
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2015年2月1日
一次修了 (実際)
2015年11月1日
研究の完了 (実際)
2016年2月1日
試験登録日
最初に提出
2012年11月19日
QC基準を満たした最初の提出物
2016年4月29日
最初の投稿 (見積もり)
2016年5月2日
学習記録の更新
投稿された最後の更新 (実際)
2017年4月6日
QC基準を満たした最後の更新が送信されました
2017年4月4日
最終確認日
2016年4月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。